Detroit mayor turned down J&J vaccine in favor of others

Friday, March 5, 2021 | David Eggert, Associated Press

Mike Duggan
In this April 23, 2020, file photo, Detroit Mayor Mike Duggan speaks in Detroit. Mayor Duggan this week turned down 6,200 doses of the newly authorized Johnson & Johnson coronavirus vaccine, with favoring shots from Pfizer and Moderna for now. "Johnson & Johnson is a very good vaccine. Moderna and Pfizer are the best," he said Thursday, March 4, 2021. "And I am going to do everything I can to make sure that residents of the city of Detroit get the best." (AP Photo/Carlos Osorio, File)

LANSING, Mich. (AP) — Detroit this week turned down 6,200 doses of the newly authorized Johnson & Johnson coronavirus vaccine, with Mayor Mike Duggan favoring shots from Pfizer and Moderna for now.

“Johnson & Johnson is a very good vaccine. Moderna and Pfizer are the best,” he said Thursday. “And I am going to do everything I can to make sure that residents of the city of Detroit get the best.”

Duggan said the allotment of 29,000 Pfizer and Moderna doses “covered everyone who wanted a vaccination this week." On Friday, he said the city will accept J&J vaccines in the state's next allocation, calling them "a key part of our expansion of vaccine centers.”

Duggan's initial comments conflicted with guidance from top state and federal health officials.

Dr. Joneigh Khaldun, Michigan's chief medical executive, said earlier in the week that people who are offered the J&J vaccine should "take it because declining ... could be the difference between life and death.” In a statement Friday, she cautioned against comparing the three vaccines — as the mayor did — because of differences in when and where each company conducted its studies, with the Pfizer and Moderna research finished before concerning variants began spreading.

In the U.S., the two-dose Pfizer and Moderna shots were 95% protective against symptomatic COVID-19. J&J’s one-dose effectiveness of 85% against severe COVID-19 dropped to 66% when moderate cases were rolled in. The Food and Drug Administration has reported that, just like its predecessors, the J&J shot offers strong protection against the worst outcomes, hospitalization and death.

“All of the vaccines are safe and effective and I recommend that all vaccines be offered in all communities,” Khaldun said.

White House coronavirus special adviser Andy Slavitt said Friday that the White House talked to the Detroit mayor's office, which called the situation a “misunderstanding.”

“In fact, he is very eager for the Johnson & Johnson vaccine,” Slavitt said of Duggan.

As of Wednesday, 11% of Detroit residents age 16 and older had gotten at least one dose. The statewide rate was 19%.

Detroit this week expanded vaccinations to any resident who is a factory worker, no matter their age or where they work. Non-residents can also get a shot if they work in manufacturing in the city.

J&J's vaccine is produced using a cell line derived from an aborted fetus, which has prompted moral concerns from Catholic leaders. The chairmen of the United States Conference of Catholic Bishops’ committees on doctrine and abortion issues said the Pfizer or Moderna vaccines are preferable “if one has the ability to choose a vaccine.”

A $4.2 billion COVID-19 relief plan approved by Michigan's Republican-led Legislature this week includes a provision that would require vaccine recipients to be informed if and in what manner their vaccine was developed with aborted fetal tissue or human embryonic stem cells. Democratic Gov. Gretchen Whitmer could declare the item unenforceable.

___

Associated Press writer Zeke Miller in Washington contributed to this report.

___

Follow David Eggert at https://twitter.com/DavidEggert00

Featured Article: Management Fee



7 Bellwether Stocks Signaling a Return to Normal

Bellwether stocks are considered to be leading indicators about the direction of the overall economy, a specific sector, or the broader market. They are predictive stocks in that investors can use the company’s earnings reports to gauge economic strength or weakness.

The traditional definition of bellwether stocks brings to mind established, blue-chip companies. They are the home of mature brands with consumer loyalty. These may be stocks that aren’t associated with exceptional growth; some may be dividend stocks.

But there’s something different about normal this time around. If it’s true (and I think it is) that the old rules no longer apply, investors need to change the way they think about bellwether stocks. Plus, let’s face it, many stocks that we might consider to be bellwether stocks have already had a bit of a vaccine rally. That means that the easy gains are gone.

With that in mind, we’ve put together this special presentation that highlights seven of what may be termed the new bellwether stocks. These are stocks that investors should be paying attention to as the economy continues to reopen.

One quality of many of these stocks is that they are either negative for 2021 or underperforming the broader market. And that means that they are likely to have a strong upside as the economy grows.

View the "7 Bellwether Stocks Signaling a Return to Normal".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)2.3$38.79+0.6%4.02%25.03Hold$38.57
Johnson & Johnson (JNJ)2.7$162.48+0.1%2.49%25.55Buy$182.62
Compare These Stocks  Add These Stocks to My Watchlist 

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.